Dipeptidyl peptidase-4 inhibitors are oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 i.e. DPP-4. It is also used to treat type 2 diabetes mellitus. The glucagon in the body increases the level of glucose in the blood, and dipeptidyl peptidase inhibitors reduce the glucagon and blood glucose level. The mechanism involves an increase in the level of incretin that inhibits glucagon release, which increases insulin secretion and decreases blood glucose levels.
MARKET SCOPE
The "Global Dipeptidyl Peptidase-4 Inhibitors Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Dipeptidyl Peptidase-4 Inhibitors market with detailed market segmentation by application and drug. The report provides key statistics on the market status of the leading Dipeptidyl Peptidase-4 Inhibitors market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on application the market is segmented into, type 2 diabetes and others.
- Based on the drug the market is segmented as, sitagliptin, vildagliptin, saxagliptin, linagliptin, gemigliptin, anagliptin, and teneligliptin.
MARKET DYNAMICS
Drivers:
- Rising prevalence of type 2 diabetes mellitus.
- Increasing patients diagnosed with type 2 diabetes mellitus.
- Extensive R&D efforts by doctors and diabetes care centers in diabetes care is expected to fuel market growth.
Restraints:
- Severe side effects like gastrointestinal problems, skin reaction, and others.
- Whereas, the high cost of treatment for diabetes is expected to restrain the market growth during the forecast period.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 concerning five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South and Central America. The Dipeptidyl Peptidase-4 Inhibitors market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both the demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides an exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South and Central America after evaluating political, economic, social, and technological factors affecting the Dipeptidyl Peptidase-4 Inhibitors market in these regions.
IMPACT OF COVID-19 ON DIPEPTIDYL PEPTIDASE-4 INHIBITORS MARKET
COVID-19 first began in Wuhan (China) in December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in the global market. Few companies have already announced possible delays in product deliveries and slumps in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the Dipeptidyl Peptidase-4 Inhibitors market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals, and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnerships & collaborations. These activities have paved the way for the expansion of business and the customer base of market players. The market payers from the Dipeptidyl Peptidase-4 Inhibitors market are anticipated to have lucrative growth opportunities in the future with the rising demand for Dipeptidyl Peptidase-4 Inhibitors in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Dipeptidyl Peptidase-4 Inhibitors market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Merck & Co., Eli Lily & Co.
- GlaxoSmithKline Plc, LG Life Sciences Ltd.
- Novartis AG
- Phoenix Corp.
- Takeda Pharmaceutical Co